Cytokinetics

CYTK

Market cap $5.69B

Overview Fund Activity

47.56 USD

-2.20

4.42%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

47.66

+0.10

0.21%

1 day

-4.42%

5 days

-8.85%

1 month

22.11%

3 months

46.16%

6 months

5.9%

Year to date

-2.8%

1 year

-15.31%

5 years

118.57%

10 years

510.53%

About: Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Employees: 498

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

371% more call options, than puts

Call options by funds: $216M | Put options by funds: $45.9M

36% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 104

1.18% more ownership

Funds ownership: 114.1% [Q1] → 115.28% (+1.18%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 12 [Q1] → 12 (+0) [Q2]

12% less funds holding

Funds holding: 352 [Q1] → 310 (-42) [Q2]

18% less capital invested

Capital invested by funds: $5.53B [Q1] → $4.55B (-$980M) [Q2]

59% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 70

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$71

49% upside

Avg. target

$80

69% upside

High target

$96

102% upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Barclays Gena Wang	$71	Overweight Maintained	3 Sep 2025
Evercore ISI Group Cory Kasimov	$80	Outperform Maintained	3 Sep 2025
Citigroup David Lebowitz	$84	Buy Maintained	2 Sep 2025
Stifel James Condulis	$96	Buy Maintained	2 Sep 2025
JMP Securities Jason N. Butler	$78	Market Outperform Reiterated	2 Sep 2025
Needham Serge Belanger	$72	Buy Reiterated	2 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 19 articles about CYTK published over the past 30 days

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Cytokinetics, Incorporated Common Stock and Sets a Lead Plaintiff Deadline of November 17, 2025

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) between December 27, 2023, to May 6, 2025, inclusive.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Cytokinetics, Incorporated Common Stock and Sets a Lead Plaintiff Deadline of November 17, 2025

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increased from the previously announced offering size of $550.0 million.

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Cytokinetics also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $82.5 million aggregate principal amount of notes.

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes

Cytokinetics, Incorporated (CYTK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Cytokinetics, Incorporated (NASDAQ:CYTK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Fady Malik - Executive Vice President of Research & Development Andrew Callos - Executive VP & Chief Commercial Officer Sung Lee - EVP & CFO Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst All right. Great. I'm Max Skor, a biotech analyst with Morgan Stanley.

Cytokinetics, Incorporated (CYTK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

CNBC Television

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Zacks Investment Research

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

Cytokinetics, Incorporated (CYTK) Presents At Citi's Biopharma Back To School Conference Transcript

Cytokinetics, Incorporated (NASDAQ:CYTK ) Citi's Biopharma Back to School Conference September 2, 2025 2:30 PM EDT Company Participants Robert I. Blum - CEO, President & Director Fady Malik - Executive Vice President of Research & Development Sung Lee - EVP & CFO Isaac Ciechanover - EVP of Corporate Development & Chief Business Officer Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Thanks everybody for coming to the Citi Biopharma Conference.

Cytokinetics, Incorporated (CYTK) Presents At Citi's Biopharma Back To School Conference Transcript

Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential

MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is significant, with U.S. peak sales scenarios ranging from ~$1.2B–$3.5B (net) depending on adoption, and higher if global and non-obstructive HCM are included. Differentiation vs. Camzyos (mavacamten) lies in aficamten's shorter half-life, faster titration, and cleaner safety profile, which may drive higher physician preference despite BMS's head start.

Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential

Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript

Cytokinetics, Incorporated -Exploring The Changing Treatment Paradigm Transcript Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Fady Malik - Executive Vice President of Research & Development Daniel Jacoby Robert I. Blum - CEO, President & Director Conference Call Participants Pablo García-Pavia - Head, Heart Failure and Inherited Cardiac Diseases Unit, Hospital Universatario Carolyn Ho - Medical Director of the Cardiovascular Genetic Center Ahmad Masri - Cardiomyopathy Section Head and Director, Hypertrophic Cardiomyopathy Center Anjali Owens - Medical Director, Inherited Cardiac Disease Presentation Diane Weiser Senior Vice President of Corporate Affairs Welcome, everyone, and thanks for joining.

Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript

Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows.

Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.

Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows.

See News Rankings

Charts implemented using Lightweight Charts™